Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 10 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

60%

6 trials in Phase 3/4

Results Transparency

40%

4 of 10 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 3

6(60.0%)

Phase 2

3(30.0%)

Phase 1

1(10.0%)

10Total

Phase 3(6)

Phase 2(3)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT00044148Phase 2Completed

The Effect of LY333531 on Protein in the Urine in Patients With Type 2 Diabetes

Role: lead

NCT00090519Phase 3Completed

Reduction in the Occurrence of Center-Involved Diabetic Macular Edema

Role: lead

NCT00266695Phase 3Completed

Treatment for Completers of the Study B7A-MC-MBCM

Role: lead

NCT00133952Phase 3Completed

Effect of Ruboxistaurin on Clinically Significant Macular Edema

Role: lead

NCT00604383Phase 3Completed

Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study

Role: lead

NCT00297401Phase 3Completed

Renal and Peripheral Hemodynamic Function in Patients With Type 1 Diabetes Mellitus

Role: lead

NCT00044408Phase 3Completed

Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes

Role: lead

NCT00190970Phase 2Completed

The Effect of Ruboxistaurin on Small Fiber Function

Role: lead

NCT00482976Phase 2Completed

Effect of LY333531 on Vascular and Neural Functions

Role: lead

NCT00552227Phase 1Completed

Isoprostane/FMD Study The Effect of Protein Kinase C (PKC) β Specific Inhibitor LY333531 on Oxidant Stress in Patients With Type 2 Diabetes Mellitus

Role: lead

All 10 trials loaded